

166



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/202,984	03/19/1999	ARMIN PETER CZERNILOFSKY	0652.1830000	3631

7590 01/13/2005

STERNE KESSLER GOLDSTEIN & FOX
1100 NEW YORK AVENUE NW
SUITE 600
WASHINGTON, DC 200053934

EXAMINER

CHUNDURU, SURYAPRABHA

ART UNIT	PAPER NUMBER
----------	--------------

1637

DATE MAILED: 01/13/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/202,984

Applicant(s)

CZERNILOFSKY ET AL.

Examiner

Suryaprabha Chunduru

Art Unit

1637

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 28 October 2004.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 61-120 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 61-120 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 10/19/04
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____

DETAILED ACTION

1. Applicants' response to the earlier office action filed on 10/28/04 has been entered.
2. Claims 1-60 are cancelled. Claims 61-120 are pending. This instant application is a 371 of PCT/EP97/03329 filed on 6/25/1997 which claims the foreign priority to the EP 96/110 459 filed on 6/28/1996.

Response to Arguments

3. Applicants' response to the office action is fully considered and found not persuasive.
4. The following is the rejection made in the previous office action under 35 USC 102(e):
 - A. Claims 61-64, 66-70, 77-83, 87-93, 95-99, 106-112, 116-120 are rejected under 35 U.S.C. 102(e) as being anticipated by Vande Woude et al. (USPN. 5,645,988).

Vande Woude et al. teach parallel screening method of claims 61-62, 90-91, of determining the pharmacological effect of a substance (anti-cancer drug) on the activity of different biological target molecules contained in test cells (cancer cells) of same type, comprising

(a) applying or contacting a drug (appropriate concentration (see column 12, lines 45-60) to test cells (cancer cells) derived from the same type of biological material (see column 11, lines 36-57), wherein the cancer cells differ in the presence of a particular target molecule (oncogene, proto oncogene, tumor suppressor genes) (see column 5, lines 39-46, column 11, lines 24-30, lines 59-67, column 12, lines 1-4, column 7, lines 1-21);

(b) measuring the effect of the substance on the biological activities (cell growth, tumor formation and the phenotypes of transformed cells (see column 7, lines 22-29) of said different target molecules using detection system (see column 5, lines 46-47, column 11, lines 30-32);

(c) comparing the effect of said test substance on the biological activities of said different target molecules, wherein said biological activities are selected from the group of metabolically coupled signal transduction (cell cycle pathway genes) (see column 5, lines 47-50, column 7, lines 30-60, column 11, lines 32-35).

With regard to claims 63-64, 66, 92-93, 95, Vande Woude et al. teach that said different target molecules include Ras (K-ras, N-ras, H-ras), vmos-raf (see column 12, lines 1-41, column 7, lines 30-50, column 1-2, table 1);

With regard to claims 61, 67-70, 96-99, Vande Woude et al. teach said biological activity is receptor-coupled signal transduction including tyrosine kinase serine/threonine kinases growth factor receptors such as EGF (see column 6, lines 20-29, column 7, lines 30-49, column 1-2, table 1);

With regard to claims 77-80, 106-109, Vande Woude et al. teach that the biological activity is a pathological effect including proliferation, or apoptosis (see column 7, lines 22-50, column 11, lines 36-58);

With regard to claims 87-89, 116-117, Vande Woude et al. teach that said test cells are mammalian cells comprising human cancer cells having same genotype (see column 11, lines 36-59, column 34, lines 49-51);

With regard to claims 90-91, Vande Woude et al. teach that said method is determines effect of a test substance on the same biological target molecule (mos) contained in test cells of different or same types but of with a different state of differentiation or activation (column 7, lines 30-49, wherein mos is differentially expressed in different stages of cell division);

With regard to claims 81-82, 110-111, Vande Woude et al. teach that said test cells are transformed with DNA operably encoding said different target molecules which include receptors (see column 13, lines 7-32, column 1-2, table.1);

With regard to claims 83, 112, Vande Woude et al. teach said detection system comprises proliferation assay, an apoptosis assay (see column 38, lines 59-67, column 39, lines 1-18, column 42, lines 54-67, column 43, lines 1-39, column 45, lines 3-17);

With regard to claims 118-120, Vande Woude et al. also teach that said test cells are from different or same types or same type with different states of differentiation and include tumor and normal cells (see column 7, lines 30-49). Thus the disclosure of Vande Woude et al. meets the limitations in the instant claims.

Response to arguments:

With regard to the above rejection, Applicants' arguments are fully considered and found not persuasive. Applicants argue that the instant specification defines parallel screening on page 6, lines 11-17 and Vande Woude et al. does not teach high throughput parallel screening as claimed in the instant claims. These arguments are fully considered and found not persuasive. First, it is noted that the instant claims recite screening of a substance and not screening of several substances in a high throughput manner as asserted. Second, the claims are interpreted in their broadest scope and the limitation upon which the assertion is based, is *not* present in the claims, that is, the limitation "a high throughput screen in which several substances are applied in parallel screen to one or more sets of cellular substrates" is not present in the claims. As stated in MPEP 2145, "Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims". In re Van Geuns, 988 F.2d 1181, 26 USPQ2d

Art Unit: 1637

1057 (Fed. Cir. 1993), the instant independent claims do not recite this limitation and specification is not be read into the claims. Applicants further argue that Vande Woude et al. does not teach different cell types containing same target molecule. These arguments are fully considered and found not persuasive because The disclosure of Vande Woude et al. does teach screening assay using different cell types (NCI panel of cell types) containing same target molecule (Ras gene) (see col. 37, table 8, col. 38, example 2, line 61-67, col.39, line 1-30). Thus the disclosure of Vande Woude et al. anticipates the limitations in the instant claims and the rejection is maintained herein.

5. The following is the rejection made in the previous office action under 35 USC 102(e):

Claims 61-62, 67-73, 77-79, 90-91, 96-102, 106-108 are rejected under 35 U.S.C. 102(e) as being anticipated by Tang et al. (USPN. 5,710,173).

Tang et al. teach parallel screening method (96-well micro titer plates) of claims 61-62, 90-91, of determining the pharmacological effect of a substance (anti-cancer drug) on the activity of different biological target molecules contained in test cells of same type, comprising

(a) applying or contacting a drug (appropriate concentration (see column 19, lines 47-49), to test cells derived from the same type of biological material, wherein the test cells differ in the presence of a particular target molecule (tyrosine kinases) (see column 10, lines 58-62);

(b) measuring the effect of the substance on the biological activities (cell growth), (see column 10, lines 62-63) of said different target molecules using detection system (see column 11, lines 4-26);

(c) comparing the effect of said test substance on the biological activities of said different target molecules, wherein said biological activities are selected from the group of metabolically

Art Unit: 1637

coupled signal transduction (tyrosine kinase pathway) (see column 11, lines 20-26, column 2, lines 25-30, column 4, lines 16-26).

With regard to claims 61, 67-71, 96-100, Tang et al. teach said biological activity is receptor-coupled signal transduction including tyrosine kinase, growth factor receptors such as EGF, HGF, VEGF (see column 5, lines 7-23, column 7, lines 49-65, column 9, lines 60-67, column 10, lines 1-29);

With regard to claims 72-73, 101-103, Tang et al. teach that said different target molecules include EGF, HGF, HER2, KDR (see column 4, lines 56-62, column 5, lines 7-23, column 7, lines 49-65, column 9, lines 60-67, column 10, lines 1-29);

With regard to claims 77-79, 106-108, Tang et al. teach that the biological activity is a pathological effect including proliferation, and differentiation (see column 4, lines 16-26). Thus the disclosure of Tang et al. meets the limitations in the instant claims.

Response to arguments:

With regard to the above rejection, Applicants' arguments are fully considered and found not persuasive. Applicants argue that the instant specification defines parallel screening on page 6, lines 11-17 and Tang et al. does not teach high throughput parallel screening as claimed in the instant claims. These arguments are fully considered and found not persuasive. First, it is noted that the instant claims recite screening of a substance and not screening of several substances in a high throughput manner as asserted. Second, the claims are interpreted in their broadest scope and the limitation upon which the assertion is based, is *not* present in the claims, that is, the limitation "a high throughput screen in which several substances are applied in parallel screen to one or more sets of cellular substrates" is not present in the claims. As stated in

Art Unit: 1637

MPEP 2145, "Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims". In re Van Geuns, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993), the instant independent claims do not recite this limitation and specification is not be read into the claims. Applicants further argue that Tang et al. does not teach assaying in a single step and does not disclose whether the cells are from the same cell type or different cell types containing same target molecule. These arguments are fully considered and found not persuasive because first, the instant claims do not recite "single step assay". Second the disclosure of Tang et al. does teach a parallel screening assay (96-well plate assay considered as single step) using same cell types (see col. 19, line 26-39) and also using different cell types having same target molecule (see col. 10, line 4-29). Thus the disclosure of Tang et al. anticipates the limitations in the instant claims and the rejection is maintained herein.

6. The following is the rejection made in the previous office action under 35 USC 103(a):

A. Claims 74-76, 84-85, 103-105, 113-114 are rejected under 35 U.S.C. 103(a) as being unpatentable over Vande Woude et al. (USPN. 5,645,988) in view of Czernilofsky et al. (USPN. 5,854,004).

Vande Woude et al. teach parallel screening method of claims 60-61, 90-91, of determining the pharmacological effect of a substance (anti-cancer drug) on the activity of different biological target molecules contained in test cells (cancer cells) of same type, comprising

(a) applying or contacting a drug (appropriate concentration (see column 12, lines 45-60)) to test cells (cancer cells) derived from the same type of biological material (see column 11, lines 36-57), wherein the cancer cells differ in the presence of a particular target molecule (oncogene,

Art Unit: 1637

proto oncogene, tumor suppressor genes) (see column 5, lines 39-46, column 11, lines 24-30, lines 59-67, column 12, lines 1-4, column 7, lines 1-21);

(b) measuring the effect of the substance on the biological activities (cell growth, tumor formation and the phenotypes of transformed cells (see column 7, lines 22-29) of said different target molecules using detection system (see column 5, lines 46-47, column 11, lines 30-32);

(c) comparing the effect of said test substance on the biological activities of said different target molecules, wherein said biological activities are selected from the group of metabolically coupled signal transduction (cell cycle pathway genes) (see column 5, lines 47-50, column 7, lines 30-60, column 11, lines 32-35). Vande Woude et al. also teach that said different target molecules include Ras (K-ras, N-ras, H-ras), vmos-raf (see column 12, lines 1-41, column 7, lines 30-50, column 1-2, table 1); Vande Woude et al. teach said biological activity is receptor-coupled signal transduction including tyrosine kinase serine/threonine kinases growth factor receptors such as EGF (see column 6, lines 20-29, column 7, lines 30-49, column 1-2, table 1).

However, Vande Woude et al. did not teach other target molecules which include other than tyrosine kinases. Serine/ threonine kinases such as G-protein coupled receptors, neurokinin receptors (neurokinin-1 neurokinin-2), or serotonin receptors (5HT₂) and detection system comprising reporter system selected from the group consisting of luciferase, alkaline phosphatase, β -glucuronidase, chloramphenicol-acetyltransferase.

Czernilofsky et al. teach a parallel screening method of determining pharmacological effect of a substance on different receptor-coupled signal pathway effector targets, wherein the method comprises transforming test cells with particular receptor gene sequences under the control of TRE-regulated reporter gene expression system to effect the signaling of a particular

Art Unit: 1637

signal transduction pathway and measuring the effect of gene expression signal in the presence of a test substance and comparing the effect with control cells (see column 8, lines 49-67, column 9, lines 1-47). Czernilofsky et al. also disclose that (i) the target receptors include receptors coupled with phospholipase C-signal transduction pathway such as serotonin receptors (5HT_{1c}, 5HT₂), human neurokinin receptors (NK1, NK2, NK3), FGF receptors, PDGF receptors (see column 14, lines 8-35); (ii) suitable reporter genes include luciferase, alkaline phosphatase, β -glucuronidase, and chloramphenicol-acetyltransferase (see column 10, lines 20-56).

Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to combine the method of determining the effect of a substance on the biological activities on target molecules as taught by Vande Woude et al. with the method of detecting effect of a substance on different target molecules linked to a reporter gene system as taught by Czernilofsky et al. to achieve an expected advantage of developing a versatile and sensitive method of detecting the effect of a substance on biological activities of a wide range of target molecules with the aid of a sensitive reporter detection system because Czernilofsky et al. taught the advantage of monitoring the effect of a test substance on multistage receptor dependent intracellular signal transduction pathway to discover pharmacologically active substances for different types of indications and with a choice of specific receptor or receptor subtypes, to distinguish with great specificity between key mechanisms in different cell systems. Further the expression of the receptor indicated by the expression of the reporter gene after the receptor has been activated by the binding to a ligand aids in cloning of receptors which are biochemically characterized (see column 17, lines 29-51).

Therefore an ordinary practitioner would have been motivated to combine the method of detecting the effect of a substance on the biological activities of different target molecules as taught by Vande Woude et al. with the different receptor target molecules linked to a reporter system as taught by Czernilofsky et al. to achieve in developing an improved and sensitive method for detecting the effect of a substance on various target molecules that activate a signal transduction pathway(s) thereby characterizing said activated target molecules and detecting the corresponding signal transduction pathway mediated by said receptor molecules. Additionally it would aid in cloning the drug or substance activated receptor molecules to develop an improved method for designing an appropriate treatment regime for a particular pathological condition in which said receptor mediated signal transduction pathway is activated.

Response to arguments:

With regard to the above rejection, Applicants' arguments are fully considered and found not persuasive. Applicants argue that the instant specification defines parallel screening on page 6, lines 11-17 and Vande Woude et al. does not teach high throughput parallel screening as claimed in the instant claims. These arguments are fully considered and found not persuasive. First, it is noted that the instant claims recite screening of a substance and not screening of several substances in a high throughput manner as asserted. Second, the claims are interpreted in their broadest scope and the limitation upon which the assertion is based, is *not* present in the claims, that is, the limitation "a high throughput screen in which several substances are applied in parallel screen to one or more sets of cellular substrates" is not present in the claims. As stated in MPEP 2145, "Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims". In re Van Geuns, 988 F.2d 1181, 26 USPQ2d

1057 (Fed. Cir. 1993), the instant independent claims do not recite this limitation and specification is not be read into the claims.

Applicants further argue that there is no motivation to combine the teachings of Vande Woude et al. with the method of Czernilofsky et al. and there would be no expectation of success as Vande Woude et al. does not teach the regulatory elements of genes assayed. Applicants' arguments are fully considered and found not persuasive. The instant claims do not recite any regulatory elements, thus the assertion that Vande Woude et al. does not teach regulatory elements is not an issue in the instant context. Further, Vande Woude et al. teach proto oncogenes such as ras genes, which are considered as regulatory elements for regulating normal cell function (see col. 7, line 3-4). With regard to no motivation or suggestion to combine the teachings, the examiner recognizes that obviousness can only be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art. See *In re Fine*, 837 F.2d 1071, 5 USPQ2d 1596 (Fed. Cir. 1988) and *In re Jones*, 958 F.2d 347, 21 USPQ2d 1941 (Fed. Cir.1992). In this case, specific motivation is provided in the rejection above, which notes that Czernilofsky et al. taught the advantage of monitoring the effect of a test substance on multistage receptor dependent intracellular signal transduction pathway to discover pharmacologically active substances for different types of indications and with a choice of specific receptor or receptor sub types, to distinguish with great specificity between key mechanisms in different cell systems. Further the expression of the receptor indicated by the expression of the reporter gene after the receptor has been activated by the binding to a ligand aids in cloning of receptors which

Art Unit: 1637

are biochemically characterized (see column 17, lines 29-51). Therefore an ordinary practitioner would have reasonable expectation of success that combining the method of detecting the effect of a substance on the biological activities of different target molecules as taught by Vande Woude et al. with the different receptor target molecules linked to a reporter system as taught by Czernilofsky et al. would result in developing an improved and sensitive method for detecting the effect of a substance on various target molecules that activate a signal transduction pathway(s) thereby characterizing said activated target molecules and detecting the corresponding signal transduction pathway mediated by said receptor molecules. Therefore the rejection is maintained herein.

7. The following is the rejection made in the previous office action under 35 USC 103(a):

Claims 86 and 115 are rejected under 35 U.S.C. 103(a) as being unpatentable over Vande Woude et al. (USPN. 5,645,988) in view of Czernilofsky et al. (USPN. 5,854,004) as applied to claims 74-76, 84-85, 103-105, 113-114 above, and further in view of Chalfie et al. (USPN.5,491,084).

Vande Woude et al. teach parallel screening method of determining the pharmacological effect of a substance (anti-cancer drug) on the activity of different biological target molecules contained in test cells (cancer cells) of same type, comprising

(a) applying or contacting a drug (appropriate concentration (see column 12, lines 45-60)) to test cells (cancer cells) derived from the same type of biological material (see column 11, lines 36-57), wherein the cancer cells differ in the presence of a particular target molecule (oncogene, proto oncogene, tumor suppressor genes) (see column 5, lines 39-46, column 11, lines 24-30, lines 59-67, column 12, lines 1-4, column 7, lines 1-21);

(b) measuring the effect of the substance on the biological activities (cell growth, tumor formation and the phenotypes of transformed cells (see column 7, lines 22-29) of said different target molecules using detection system (see column 5, lines 46-47, column 11, lines 30-32);

(c) comparing the effect of said test substance on the biological activities of said different target molecules, wherein said biological activities are selected from the group of metabolically coupled signal transduction (cell cycle pathway genes) (see column 5, lines 47-50, column 7, lines 30-60, column 11, lines 32-35). Vande Woude et al. also teach that said different target molecules include Ras (K-ras, N-ras, H-ras), vmos-raf (see column 12, lines 1-41, column 7, lines 30-50, column 1-2, table 1); Vande Woude et al. teach said biological activity is receptor-coupled signal transduction including tyrosine kinase serine/threonine kinases growth factor receptors such as EGF (see column 6, lines 20-29, column 7, lines 30-49, column 1-2, table 1).

Vande Woude et al. did not teach other target molecules which include other than tyrosine kinases. Serine/ threonine kinases such as G-protein coupled receptors, neurokinin receptors (neurokinin-1 neurokinin-2), or serotonin receptors (5HT₂) and detection system comprising reporter system selected from the group consisting of luciferase, alkaline phosphatase, β -glucuronidase, chloramphenicol-acetyltransferase.

Czernilofsky et al. teach a parallel screening method of determining pharmacological effect of a substance on different receptor-coupled signal pathway effector targets, wherein the method comprises transforming test cells with particular receptor gene sequences under the control of TRE-regulated reporter gene expression system to effect the signaling of a particular signal transduction pathway and measuring the effect of gene expression signal in the presence of a test substance and comparing the effect with control cells (see column 8, lines 49-67,

Art Unit: 1637

column 9, lines 1-47). Czernilofsky et al. also disclose that (i) the target receptors include receptors coupled with phospholipase C-signal transduction pathway such as serotonin receptors (5HT_{1c}, 5HT₂), human neurokinin receptors (NK1, NK2, NK3), FGF receptors, PDGF receptors (see column 14, lines 8-35); (ii) suitable reporter genes include luciferase, alkaline phosphatase, β -glucuronidase, and chloramphenicol-acetyltransferase (see column 10, lines 20-56).

Neither Vande Woude et al. nor Czernilofsky et al. teach green fluorescent protein as a reporter gene.

Chalfie et al. teach a method for cells expressing a biological activity (gene expression) of a particular target molecule, wherein the regulatory sequences of a target molecule are linked to a reporter fluorescent protein which fluoresces when said target is expressed within the cells (see column 1, lines 38-52). Chalfie et al. also teach that said reporter fluorescent protein is a gene encoding a green fluorescent protein (column 1, lines 38-41).

Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to combine the method of determining the effect of a substance on the biological activities on target molecules as taught by Vande Woude et al. with the method of detecting effect of a substance on different target molecules linked to a reporter gene system as taught by Czernilofsky et al. to achieve an expected advantage of developing a versatile and sensitive method of detecting the effect of a substance on biological activities of a wide range of target molecules with the aid of a sensitive reporter detection system because Czernilofsky et al. taught the advantage of monitoring the effect of a test substance on multistage receptor dependent intracellular signal transduction pathway to discover pharmacologically active substances for different types of indications and with a choice of specific receptor or receptor sub

types, to distinguish with great specificity between key mechanisms in different cell systems. Further the expression of the receptor indicated by the expression of the reporter gene after the receptor has been activated by the binding to a ligand aids in cloning of receptors which are biochemically characterized (see column 17, lines 29-51).

Therefore an ordinary practitioner would have been motivated to combine the method of detecting the effect of a substance on the biological activities of different target molecules as taught by Vande Woude et al. with the different receptor target molecules linked to a reporter system as taught by Czernilofsky et al. to achieve in developing an improved and sensitive method for detecting the effect of a substance on various target molecules that activate a signal transduction pathway(s) thereby characterizing said activated target molecules and detecting the corresponding signal transduction pathway mediated by said receptor molecules. Additionally it would aid in cloning the drug or substance activated receptor molecules to develop an improved method for designing an appropriate treatment regime for a particular pathological condition in which said receptor mediated signal transduction pathway is activated.

Further it would have been obvious to combine the reporter gene mediated detection of the effect of a substance on the biological activities with the method of selecting or localizing a biological activity within the cells using the reporter gene encoding a green fluorescent protein as taught by Chalfie et al. to achieve an enhanced sensitivity in determining the effect of a substance on the biological activity or activities because Chalfie et al. taught that the biological activity of a particular target molecule in response to an external stimulus can be monitored within the cells containing the target by the expression of green fluorescence protein linked to said target and the cells expressing the GFP can be easily selected and sorted by a fluorescent-

activated sorter (see column 4, lines 3-12). Therefore an ordinary practitioner would have motivated to combine the reporter gene mediated detection method of determining the effect of a substance on the biological activity with the method of selecting or localizing a biological activity within the cells using the reporter gene encoding a green fluorescent protein as taught by Chalfie et al. to enhance the detection of the biological activity of a target molecule within the cells, so as to detect and sort the cells expressing the target molecules without lysing the cells.

Response to arguments:

With regard to the rejection above, Applicants' arguments are fully considered and found not persuasive. Applicants' argue that the instant claims are not obvious over Vande Woude et al. in view of Czernilofsky and further in view of Chalfie et al. since the references do not teach or suggest the claimed invention. Applicants' arguments are fully considered and found not persuasive. As discussed above Vande Woude et al. in view of Czernilofsky et al. does teach the claimed invention obvious and as discussed above rejection it would have been obvious to combine the reporter gene mediated detection of the effect of a substance on the biological activities with the method of selecting or localizing a biological activity within the cells using the reporter gene encoding a green fluorescent protein as taught by Chalfie et al. to achieve an enhanced sensitivity in determining the effect of a substance on the biological activity or activities because Chalfie et al. taught that the biological activity of a particular target molecule in response to an external stimulus can be monitored within the cells containing the target by the expression of green fluorescence protein linked to said target and the cells expressing the GFP can be easily selected and sorted by a fluorescent-activated sorter (see column 4, lines 3-12). Therefore an ordinary practitioner would have motivated to combine the reporter gene mediated

Art Unit: 1637

detection method of determining the effect of a substance on the biological activity with the method of selecting or localizing a biological activity within the cells using the reporter gene encoding a green fluorescent protein as taught by Chalfie et al. to enhance the detection of the biological activity of a target molecule within the cells, so as to detect and sort the cells expressing the target molecules without lysing the cells. Therefore the rejection is maintained herein.

8. The following is the rejection made in the previous office action under 35 USC 103(a):

C. Claims 65, and 94 are rejected under 35 U.S.C. 103(a) as being unpatentable over Vande Woude et al. (USPN. 5,645,988) in view of Reed et al. (USPN. 5,686,595).

Vande Woude et al. teach parallel screening method of determining the pharmacological effect of a substance (anti-cancer drug) on the activity of different biological target molecules contained in test cells (cancer cells) of same type, comprising

(a) applying or contacting a drug (appropriate concentration (see column 12, lines 45-60)) to test cells (cancer cells) derived from the same type of biological material (see column 11, lines 36-57), wherein the cancer cells differ in the presence of a particular target molecule (oncogene, proto oncogene, tumor suppressor genes) (see column 5, lines 39-46, column 11, lines 24-30, lines 59-67, column 12, lines 1-4, column 7, lines 1-21);

(b) measuring the effect of the substance on the biological activities (cell growth, tumor formation and the phenotypes of transformed cells (see column 7, lines 22-29) of said different target molecules using detection system (see column 5, lines 46-47, column 11, lines 30-32);

(c) comparing the effect of said test substance on the biological activities of said different target molecules, wherein said biological activities are selected from the group of metabolically

Art Unit: 1637

coupled signal transduction (cell cycle pathway genes) (see column 5, lines 47-50, column 7, lines 30-60, column 11, lines 32-35). Vande Woude et al. also teach that said different target molecules include Ras (K-ras, N-ras, H-ras), vmos-raf (see column 12, lines 1-41, column 7, lines 30-50, column 1-2, table 1); Vande Woude et al. teach said biological activity is receptor-coupled signal transduction including tyrosine kinase serine/threonine kinases growth factor receptors such as EGF (see column 6, lines 20-29, column 7, lines 30-49, column 1-2, table 1). However, Vande Woude et al. did not teach other target molecules which include Bcl-2.

Reed et al. teach a method for screening agents that inhibit binding of Bcl-2 related polypeptide with Bcl-2 target molecule (see column 8, lines 15-27), Reed et al. also teach regulation of Bcl-2 expression by modulating the binding properties of Bcl-2 with Bcl-2-related agents in cancer cells would reduce the level of free Bcl-2 in a cell and modulate the susceptibility of a cell to apoptosis (see column 24-49).

Therefore an ordinary practitioner would have been motivated to combine the method of detecting the effect of a substance on the biological activity of different target molecules as taught by Vande Woude et al. with the different target molecules as taught by Reed et al. to achieve in developing an improved method for detecting the effect of a substance on a wide range of target molecules that affect not only cell proliferation activity but also apoptosis activity because Reed et al. taught the advantage of monitoring Bcl-2 expression in apoptosis which enables to discover pharmacologically active substances that modulate the expression of Bcl-2 and apoptosis (see column 11, lines 45-49). An ordinary practitioner would have been motivated to combine the method of detecting the effect of a substance on the biological activity of different target molecules of Vande Woude et al. with inclusion of Bcl-2 target molecule

Art Unit: 1637

which would result in improving the method of detecting the effect of a substance on not only the biological activity related to cell proliferation but also the effect of a substance on the biological activity related to apoptosis which would also aid in identifying drug targets related to apoptosis.

Response to arguments:

With regard to the above rejection, Applicants' arguments are fully considered and found not persuasive. Applicants argue that the instant specification defines parallel screening on page 6, lines 11-17 and Vande Woude et al. does not teach high throughput parallel screening as claimed in the instant claims. These arguments are fully considered and found not persuasive. First, it is noted that the instant claims recite screening of a substance and not screening of several substances in a high throughput manner as asserted. Second, the claims are interpreted in their broadest scope and the limitation upon which the assertion is based, is *not* present in the claims, that is, the limitation "a high throughput screen in which several substances are applied in parallel screen to one or more sets of cellular substrates" is not present in the claims. As stated in MPEP 2145, "Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims". In re Van Geuns, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993), the instant independent claims do not recite this limitation and specification is not be read into the claims.

Applicants further argue that the combination of teachings of Vande Woude et al. in view of Reed et al. would not make the instant claims obvious and the combination would not have any reasonable expectation of success. Applicants arguments are fully considered and found not persuasive. As discussed in the above rejection an ordinary practitioner would have

been motivated to combine the method of detecting the effect of a substance on the biological activity of different target molecules as taught by Vande Woude et al. with the different target molecules as taught by Reed et al. to achieve in developing an improved and method for detecting the effect of a substance on a wide range of target molecules that affect not only cell proliferation activity but also apoptosis activity because Reed et al. taught the advantage of monitoring Bcl-2 expression in apoptosis which enables to discover pharmacologically active substances that modulate the expression of Bcl-2 and apoptosis (see column 11, lines 45-49). An ordinary practitioner would have been motivated to combine the method of detecting the effect of a substance on the biological activity of different target molecules of Vande Woude et al. with inclusion of Bcl-2 target molecule which would result in improving the method of detecting the effect of a substance on not only the biological activity related to cell proliferation but also the effect of a substance on the biological activity related to apoptosis which would also aid in identifying drug targets related to apoptosis. Therefore the rejection is maintained herein.

Conclusion

No claims are allowable.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37


Art Unit: 1637

CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Suryaprabha Chunduru whose telephone number is 571-272-0783. The examiner can normally be reached on 8.30A.M. - 4.30P.M, Mon - Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 571-272-0782. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and - for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.


Suryaprabha Chunduru
January 5, 2005


JEFFREY FREDMAN
PRIMARY EXAMINER

1/7/05